Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on October 4, 2023. The filing serves as a Regulation FD disclosure regarding a presentation by CEO Antony Mattessich at the EURETINA Innovation Spotlight (EIS). The presentation focuses on the Company's clinical development program for OTX-TKI, a candidate for treating wet age-related macular degeneration.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the scheduled presentation of clinical development updates.
Guidance, Outlook, and Risks
The Company is providing an update on its clinical development program for OTX-TKI. The filing explicitly states that the information, including the attached slide presentation (Exhibit 99.1), is deemed "furnished" and not "filed" under the Securities Exchange Act of 1934. Consequently, this information shall not be deemed incorporated by reference in other filings except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the content of the slide presentation included as Exhibit 99.1 for specific clinical data on OTX-TKI.
- Confirm the status of the wet age-related macular degeneration clinical trials referenced in the presentation.
- Note that this filing does not constitute a formal financial update; refer to the most recent 10-Q or 10-K for financial metrics.